# v4.15

## Related releases

## Data changes

### Gene

```
MAP3K21 Gene Summary Updated
MAP3K21 Gene Background Updated
NQO1 Gene Summary Updated
NQO1 Gene Background Updated
POU2F2 Gene Summary Updated
POU2F2 Gene Background Updated
RPS15 Gene Background Updated
RPS15 Gene Summary Updated
```

### Alteration

```
AKT1 Oncogenic Mutations {excluding E17K} Name Changed
	 New: Oncogenic Mutations {excluding E17K}
	 Old: Oncogenic Mutations
AKT1 E17K, Mutation Effect Description Updated
ATM Truncating Mutations, Mutation Effect Description Updated
BRAF L485W, Oncogenicity Updated
	 New: Inconclusive
	 Old: Likely
BRCA1 S1140G, Mutation Effect Description Updated
BRCA1 L440S Added
EGFR G719C, Mutation Effect Description Updated
EGFR D770_N771insSVD, Mutation Effect Description Updated
EGFR S768T Added
EGFR G779F, Mutation Effect Description Updated
KIT V560E (Exon 11), Oncogenicity Updated
	 New: Likely
	 Old: Inconclusive
MAP3K21 Gene Type Updated
MAP3K21 Amplification Added
NQO1 Gene Type Updated
NQO1 Amplification Added
NTRK3 ETV6-NTRK3 Fusion, Mutation Effect Description Updated
PDGFRA V658A, Mutation Effect Description Updated
PDGFRA N659K, Mutation Effect Description Updated
PDGFRA D842H Added
PDGFRA D842N Added
PDGFRA G680R Added
PDGFRA Y676C Added
PDGFRB E472D Added
PDGFRB P596L Added
PIK3CA E545V Added
PIK3CA M1004V Added
PIK3CA Q75E Added
PIK3CA C90Y Added
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R} Name Changed
	 New: Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}
	 Old: Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y}
POU2F2 Gene Type Updated
POU2F2 Amplification Added
RPS15 Gene Type Updated
RPS15 Amplification Added
RPS15 P131S Added
RPS15 G132S Added
RPS15 G134R Added
RPS15 S138F Added
RPS15 H137Y Added
RPS15 T136A Added
SETD2 R2510H Added
STAT6 NAB2-STAT6 Fusion Added
```

### Evidence

```
AKT1 Oncogenic Mutations {excluding E17K}, Breast Cancer, Tumor Type Summary Updated
AKT1 Oncogenic Mutations {excluding E17K}, Breast Cancer, Capivasertib + Fulvestrant 2 Updated
AKT1 Oncogenic Mutations {excluding E17K}, Other Tumor Types, Tumor Type Summary Updated
AKT1 E17K, Breast Cancer Added
AKT1 Oncogenic Mutations {excluding E17K}, Breast Cancer, Capivasertib + Fulvestrant  Updated
AKT1 E17K, Breast Cancer, Capivasertib + Fulvestrant  Updated
AKT1 E17K, Other Solid Tumor Types Added
BRAF K601, All Solid Tumors, PLX8394  Updated
BRAF G469A, G469V, G469R, G464 (non-V600 mutations class II ), All Solid Tumors, PLX8394  Updated
EGFR G724S, Non-Small Cell Lung Cancer, Tumor Type Summary Updated
EGFR G724S, Non-Small Cell Lung Cancer, Afatinib 3A Added
EGFR G724S, Non-Small Cell Lung Cancer, Osimertinib  Updated
EGFR G724S, Other Solid Tumor Types Added
EGFR L718Q, Other Solid Tumor Types Added
EGFR L792F, Non-Small Cell Lung Cancer Added
EGFR L718V, Non-Small Cell Lung Cancer, Tumor Type Summary Updated
EGFR L718V, Non-Small Cell Lung Cancer, Afatinib 3A Updated
EGFR L718V, Non-Small Cell Lung Cancer, Osimertinib  Updated
EGFR L718Q, Non-Small Cell Lung Cancer Added
EGFR L718V, Other Solid Tumor Types Added
EGFR L718Q, Non-Small Cell Lung Cancer, Tumor Type Summary Updated
EGFR L718Q, Other Solid Tumor Types, Tumor Type Summary Updated
EGFR L718V, Other Solid Tumor Types, Tumor Type Summary Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Tumor Type Summary Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy 1 Added
EGFR G724S, Other Solid Tumor Types, Tumor Type Summary Updated
EGFR Oncogenic Mutations, Other Tumor Types, Tumor Type Summary Updated
EGFR L792F, Non-Small Cell Lung Cancer, Tumor Type Summary Updated
EGFR L792F, Other Solid Tumor Types Added
EGFR L792H, Other Solid Tumor Types Added
EGFR L718V, Non-Small Cell Lung Cancer, Afatinib  Updated
FGFR1 Amplification, Lung Squamous Cell Carcinoma Deleted
FGFR1 Amplification, Other Tumor Types Deleted
FLT3 572_630ins [Internal tandem duplication], D835, I836, Acute Myeloid Leukemia, Gilteritinib  Updated
KRAS G12C, Non-Small Cell Lung Cancer, Sotorasib  Updated
KRAS G12C, Non-Small Cell Lung Cancer, Adagrasib  Updated
KRAS G12C, Ampullary Cancer Added
MDM2 Amplification, Biliary Tract Cancer, NOS Added
MDM2 Amplification, All Solid Tumors, Brigimadlin 4 Added
MDM2 Amplification, All Solid Tumors Name Changed
	 New: All Solid Tumors
	 Old: Other Solid Tumor Types
MDM2 Amplification, All Solid Tumors, Tumor Type Summary Updated
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Breast Cancer, Capivasertib + Fulvestrant 1 Added
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Other Tumor Types, Tumor Type Summary Updated
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R Added
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Tumor Type Summary Updated
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Alpelisib + Fulvestrant  Updated
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Capivasertib + Fulvestrant 2 Added
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Other Tumor Types, Tumor Type Summary Updated
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Breast Cancer, Tumor Type Summary Updated
PIK3CA Oncogenic Mutations, Breast Cancer, Capivasertib + Fulvestrant 1 Deleted
PIK3CA Oncogenic Mutations, Breast Cancer, Tumor Type Summary Updated
PIK3CA H1047R, Breast Cancer, Tumor Type Summary Updated
PIK3CA C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R, H1047Y, Breast Cancer, Capivasertib + Fulvestrant  Updated
PIK3CA Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y; R88Q; N345K; E545Q; Q546K; Q546P; M1043V; M1043I; G1049R}, Breast Cancer, Capivasertib + Fulvestrant  Updated
PIK3CA R88Q, N345K, E545Q, Q546K, Q546P, M1043V, M1043I, G1049R, Breast Cancer, Capivasertib + Fulvestrant  Updated
```
